- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05815160
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
A Phase 1 Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
The primary purpose of part 1 (dose escalation) of this study is to identify the recommended phase 2 dose (RP2D) and to characterize the safety and tolerability of Debio 0123 in combination with carboplatin and etoposide.
The primary purpose of part 2 (dose expansion) of this study is to characterize the safety and tolerability of Debio 0123 at the RP2D when administered in combination with carboplatin and etoposide.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Debiopharm International S.A
- Phone Number: +41 21 321 01 11
- Email: clinicaltrials@debiopharm.com
Study Locations
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitario Vall d'Hebron
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28027
- Recruiting
- Clinica Universidad de Navarra
-
Madrid, Spain, 28050
- Recruiting
- Hospital Universitario HM Sanchinarro. START Madrid - Centro Integral Oncológico Clara Campal (CIOCC)
-
Pamplona, Spain, 31008
- Recruiting
- Clinica Universidad de Navarra
-
Valencia, Spain, 46010
- Recruiting
- Hospital Clínico Universitario de Valencia
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- University of Arkansas for Medical Sciences
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Health System
-
-
New York
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically or cytologically confirmed SCLC
- Tumor that is not bleeding
Prior platinum-based chemotherapy (carboplatin and/or cisplatin)
- Part 1 (dose escalation): Recurrence or progression after a minimum of 45 days since the last dose of prior standard platinum-based therapy
- Part 2 (expansion): Recurrence or progression after a minimum of 90 days since the last dose of prior standard platinum-based therapy
- Measurable disease per RECIST 1.1
- Willingness and ability to undergo tumor biopsy unless an archived tumor sample is available
- ECOG performance status of 0-1
- Life expectancy of at least 3 months in the best judgment of the Investigator
- Adequate bone marrow, hepatic and renal function, adequate coagulation status
- Willingness and ability to comply with scheduled visits, study treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria:
- Use of an investigational agent or medical device within 28 days prior to first dose of study treatment.
- History of other malignancies requiring active treatment in the last 2 years prior to first dose of study treatment, except for superficial bladder cancers, ductal carcinoma in situ or other carcinomas in situ, and non-melanoma skin cancers (basal cell/squamous cell skin cancer) that have been treated with curative intent.
- History of myocardial infarction or stroke in the last 6 months prior to first dose of study treatment, congestive heart failure greater than New York Heart Association (NYHA) class II, unstable angina pectoris, unexplained recurrent syncope, cardiac arrhythmia requiring treatment, known family history of sudden death from cardiac-related causes before the age of 50, or any cardiotoxicity experienced after previous chemotherapy.
- Left ventricular ejection fraction (LVEF) below 55%.
- QTcF >450 ms, history of congenital long QT syndrome, or clinically significant conduction abnormality, or any conduction abnormality that may increase the risk of TdP.
- Clinically significant gastrointestinal abnormality that could affect the absorption of orally administered drugs
- Major surgery ≤4 weeks prior to first dose of study treatment or incomplete recovery from the surgical procedure at the time of the first dose of study treatment.
- Radiographic findings showing tumor involvement with large blood vessels or poor demarcation from them with increased risk for bleeding.
- Radiographic findings of Interstitial lung disease (ILD) that are considered clinically significant.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
- Any infection requiring the systemic use of an antibiotic or antiviral agent.
- Known Hepatitis C virus (HCV), Hepatitis B virus (HBV), or Human Immunodeficiency Virus (HIV) infection. Participants with past infections that have been cured may be enrolled.
- Immunization with live or live-attenuated vaccine within 28 days prior to first dose of study treatment.
- Inability or unwillingness to swallow oral medications.
- Chemotherapy, monoclonal antibodies/biologics, or radiotherapy with curative intent within 28 days prior to first dose of study treatment. Palliative radiation is allowed up to 1 week prior to study treatment start.
- Unresolved AEs or toxicities due to previous treatments >Grade 1. Note: Participants with ≤Grade 2 alopecia or endocrinopathies controlled by replacement therapy are exceptions and may qualify for the study.
- Hypersensitivity to Debio 0123, etoposide or carboplatin, or any of the excipients found in the formulations for Debio 0123, etoposide, or carboplatin. If a prior hypersensitivity to carboplatin has been observed but a successful desensitization was performed for the participant, he or she may be eligible for the study.
- Prior exposure to any WEE1 inhibitor
Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Dose Escalation: Debio 0123 + Etoposide + Carboplatin
Participants will receive Debio 0123 escalating doses, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.
|
Administered as capsules.
Administered as IV infusion.
Administered as IV infusion.
|
Experimental: Part 2: Dose Expansion: Debio 0123 + Etoposide + Carboplatin
Participants will receive Debio 0123 RP2D determined in Part 1 of the study, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.
|
Administered as capsules.
Administered as IV infusion.
Administered as IV infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
Time Frame: Cycle 1 (Cycle=21 days)
|
Cycle 1 (Cycle=21 days)
|
Parts 1 and 2: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE)
Time Frame: Approximately up to 44 months
|
Approximately up to 44 months
|
Parts 1 and 2: Number of Participants With Clinically Significant Abnormalities in Laboratory, Vital Signs, Electrocardiogram (ECG), and Echocardiogram Parameters
Time Frame: Approximately up to 44 months
|
Approximately up to 44 months
|
Parts 1 and 2: Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS)
Time Frame: Baseline up to approximately 44 months
|
Baseline up to approximately 44 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Parts 1 and 2: Trough Concentration (Ctrough) of Debio 0123 and its Metabolite
Time Frame: For Part 1: Predose from Day 2 to Day 11 of Cycle 1; For Part 2: Predose from Day 3 to Day 10 of Cycle 1 and only Day 8 of subsequent cycles (Cycle=21 days)
|
For Part 1: Predose from Day 2 to Day 11 of Cycle 1; For Part 2: Predose from Day 3 to Day 10 of Cycle 1 and only Day 8 of subsequent cycles (Cycle=21 days)
|
Parts 1 and 2: Maximum Plasma Concentration (Cmax) of Debio 0123 and its Metabolite
Time Frame: For Part 1: Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days); For Part 2: Will be derived from the population Pharmacokinetic (PK) model using the sparse samples collected
|
For Part 1: Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days); For Part 2: Will be derived from the population Pharmacokinetic (PK) model using the sparse samples collected
|
Parts 1 and 2: Area Under the Concentration Curve Over 24 hours (AUC24h) of Debio 0123 and its Metabolite
Time Frame: For Part 1: Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days); For Part 2: Will be derived from the population PK model using the sparse samples collected
|
For Part 1: Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days); For Part 2: Will be derived from the population PK model using the sparse samples collected
|
Part 1: Time to Maximum Plasma Concentration (tmax) of Debio 0123 and its Metabolite
Time Frame: Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days)
|
Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days)
|
Part 1: Area Under the Concentration Curve up to the Last Measurable Concentration (AUClast) of Debio 0123 and its Metabolite
Time Frame: Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
|
Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
|
Part 1: Area Under the Concentration Curve up to Infinity (AUCinf) of Debio 0123 and its Metabolite
Time Frame: Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
|
Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
|
Part 1: Apparent Terminal Half-life (t1/2) of Debio 0123 and its Metabolite
Time Frame: Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
|
Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
|
Part 1: Apparent Clearance (CL/F) of Debio 0123
Time Frame: Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
|
Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
|
Part 1: Apparent Volume of Distribution (Vd/F) of Debio 0123
Time Frame: Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
|
Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
|
Part 1: Maximum Plasma Concentration (Cmax) of Etoposide
Time Frame: Multiple timepoints from administration to post dose from Day 1 to Day 3 of Cycle 1 (Cycle=21 days)]
|
Multiple timepoints from administration to post dose from Day 1 to Day 3 of Cycle 1 (Cycle=21 days)]
|
Part 1: Area Under the Concentration Curve Over 24 hours (AUC24h) of Etoposide
Time Frame: Multiple timepoints post dose from Day 1 to Day 5 of Cycle 1 (Cycle=21 days)
|
Multiple timepoints post dose from Day 1 to Day 5 of Cycle 1 (Cycle=21 days)
|
Part 1: Trough Concentration (Ctrough) of Etoposide
Time Frame: Predose from Day 2 to Day 5 of Cycle 1 (Cycle=21 days)
|
Predose from Day 2 to Day 5 of Cycle 1 (Cycle=21 days)
|
Part 1: Maximum Plasma Concentration (Cmax) of Carboplatin
Time Frame: Multiple timepoints from administration up to 6 hours post dose on Day 1 of Cycle 1 (Cycle=21 days)
|
Multiple timepoints from administration up to 6 hours post dose on Day 1 of Cycle 1 (Cycle=21 days)
|
Parts 1 and 2: Percentage of Participants With Best Overall Response (BOR) Assessed as per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria
Time Frame: From the start of study treatment until disease progression or end of study (up to approximately 44 months)
|
From the start of study treatment until disease progression or end of study (up to approximately 44 months)
|
Parts 1 and 2: Percentage of Participants With Objective Response (OR) Assessed as per RECIST 1.1 Criteria
Time Frame: Up to end of study (approximately 44 months)
|
Up to end of study (approximately 44 months)
|
Parts 1 and 2: Percentage of Participants With Disease Control (DC) Assessed as per RECIST 1.1 Criteria
Time Frame: From the start of study treatment until disease progression or end of study (up to approximately 44 months)
|
From the start of study treatment until disease progression or end of study (up to approximately 44 months)
|
Parts 1 and 2: Duration of Response (DOR) Assessed as per RECIST 1.1 Criteria
Time Frame: Up to disease progression or end of study (approximately 44 months)
|
Up to disease progression or end of study (approximately 44 months)
|
Parts 1 and 2: Progression Free Survival (PFS) Assessed as per RECIST 1.1 Criteria
Time Frame: From the start of study treatment until disease progression or death or end of study (up to approximately 44 months)
|
From the start of study treatment until disease progression or death or end of study (up to approximately 44 months)
|
Part 2: Overall Survival
Time Frame: From the start of study treatment until death from any cause or end of study (up to approximately 44 months
|
From the start of study treatment until death from any cause or end of study (up to approximately 44 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Carboplatin
- Etoposide
Other Study ID Numbers
- Debio 0123-SCLC-104
- 2022-001976-32 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Cancer Recurrent
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
University of Colorado, DenverAriad PharmaceuticalsCompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Adenocarcinoma of the LungUnited States
-
Bristol-Myers SquibbActive, not recruitingNon-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung CancerAustralia, Russian Federation, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Spain, Switzerland, United Kingdom
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyCompletedNon-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung CancerUnited States
-
Luye Pharma Group Ltd.UnknownNon Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer RecurrentChina
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers Squibb; Jazz PharmaceuticalsTerminatedSmall-cell Lung Cancer | Relapsed Small Cell Lung Cancer | Recurrent Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerCanada
Clinical Trials on Debio 0123
-
Debiopharm International SARecruitingAdvanced Solid TumorsSpain, United States, Switzerland
-
Debiopharm International SARecruitingAdvanced Solid TumorsNetherlands, Spain
-
Debiopharm International SARecruitingAstrocytoma, Grade III | Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeSpain, United States, Switzerland
-
Debiopharm International SACaris Life Sciences; Optimal Research (Just In Time sites)TerminatedSolid TumorUnited States, Spain, Austria, Czechia, Denmark, Russian Federation, United Kingdom, Greece, Norway, Korea, Republic of, France, Taiwan, Netherlands, Bulgaria, Finland, Ukraine, Australia, Brazil, Croatia, Philippines, Poland, Rom... and more
-
Debiopharm International SACompletedNeoplasms | Lymphoma | Cancer | Solid TumorsFrance
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...Merck KGaA, Darmstadt, GermanyCompleted
-
National Cancer Institute (NCI)TerminatedOsteosarcoma | Neuroblastoma | Rhabdomyosarcoma | Ewing's SarcomaUnited States
-
Debiopharm International SACompletedLymphoma | Cancer | Solid Tumors | MalignancyUnited States
-
University College London HospitalsBaxter BioScienceUnknown
-
Debiopharm International SACompleted